PREDICTIVE GENES, MECHANISMS, AND CLINICAL BIOMARKERS OF SUDEP

SUDEP 的预测基因、机制和临床生物标志物

• 批准号: 8234288
• 负责人: Jeffrey Noebels
• 金额: $ 51.81万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-26 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8234288
• 关键词: Accounting; Affect; Age; Arrhythmia; Basic Science; Biological; Biological Assay; Biological Markers; Biology; Blood Vessels; Brain; Brain Stem; Calcium; Candidate Disease Gene; Cardiac; Cause of Death; Cessation of life; Chicago; Classification; Clinic; Clinical; Clinical Investigator; Collection; Complex; Critiques; DNA; Defect; Development; Diagnostic; Distress; Engineering; Epilepsy; Evaluation; Experimental Models; Functional disorder; Gene Mutation; General Population; Genes; Genetic; Genetic Risk; Goals; Heart; Homeostasis; Human; Hypoxemia; Individual; Investigation; Ion Channel; Iowa; Laboratories; Lead; Link; Measures; Mechanical Ventilators; Mediating; Michigan; Modeling; Molecular; Monitor; Mutation; Myocardium; Neocortex; Pathway interactions; Patients; Periodicity; Persons; Pharmaceutical Preparations; Pharmacology; Phase; Phenotype; Physiology; Population; Premature Mortality; Receptor Gene; Research; Research Personnel; Risk; Risk Assessment; Risk Factors; Sampling; Screening procedure; Seizures; Signal Transduction; Smooth Muscle; Stem cells; Study Section; Sudden Death; Sudden infant death syndrome; Symptoms; Syndrome; Therapeutic Intervention; Time; Translating; Translational Research; Update; Variant; Ventilatory Depression; Work; Writing; autonomic nerve; base; bench to bedside; high risk; in vivo; induced pluripotent stem cell; life history; meetings; mortality; mouse model; multidisciplinary; nervous system disorder; neurogenetics; novel; preclinical efficacy; preclinical safety; prevent; programs; prospective; receptor; repository; research clinical testing; respiratory; response; tool

DESCRIPTION (provided by applicant): Unexplained collapse of cardiac and respiratory rhythmicity is a final common mechanism for SUDEP, a major and preventable cause of death in persons with epilepsy. Recent evidence shows that dysfunctional ion channels and receptors co-expressed in brain, autonomic, heart, and respiratory pathways, along with clinical measures of functional disturbances in these pathways at times surrounding seizures represent detectable and potentially treatable risk factors for SUDEP. This proposal describes an integrated multicenter and multidisciplinary collaborative project that will combine a basic science, human neurogenetics, and clinical physiology approaches to these biological risk factors in a bench to bedside translational research program to identify, validate, and clinically evaluate predictive biomarkers and preventative treatments for SUDEP. The SUDEP Center Research Pipeline will consist of a serially interrelated work flow among 6 investigators in the center. Project 1 (Baylor) will expand the repository of DNA samples from patient at 3 centers (EMU, Dravet Syndrome Clinic, SUDEP DNA Repository) and other national networks which will be analyzed using chip microarrays for >247 prioritized ion channel and receptor genes mediating cardiac arrhythmias, respiratory depression and epilepsy. Projects 2-4 (Baylor U. Michigan, U. Iowa) analyze the biology, physiology, and pharmacology of these and related gene mutations at the cellular and in vivo level in SUDEP mouse models and induced pluripotent stem cells from Dravet Syndrome cases in order to understand and validate the SUDEP phenotypes. Project 5 (U.C. Davis/Childrens Memorial Chicago) will refine clinical respiratory and cardiac biomarkers obtained during epilepsy monitoring of individuals with Dravet Syndrome and others at high risk of sudden death (ictal hypoxemia, cardiac arrhythmia). Once validated, genes from these cases are added to an incremental diagnostic chip in development at Baylor for routine patient risk assessment in clinics in individuals with other clinical biomarkers. PUBLIC HEALTH RELEVANCE: Sudden unexpected death in epilepsy (SUDEP) is the leading cause of premature mortality in idiopathic epilepsy. Preventing SUDEP depends upon identifying biologically predictive risk factors in individuals with epilepsy and using them to mak appropriate therapeutic interventions. The goal of this program is to validate a combined genetic/clinical SUDEP risk profile to screen and treat individuals with epilepsy. Disclaimer: Please note that the following critiques were prepared by the reviewers prior to the Study Section meeting and are provided in an essentially unedited form. While there is opportunity for the reviewers to update or revise their written evaluation, based upon the group's discussion, there is no guarantee that individual critiques have been updated subsequent to the discussion at the meeting. Therefore, the critiques may not fully reflect the final opinions of th individual reviewers at the close of group discussion or the final majority opinion of the group. Thus the Resume and Summary of Discussion is the final word on what the reviewers actually considered critical at the meeting.

描述（由申请人提供）：不明原因的心脏和呼吸节律性崩溃是SUDEP的最终常见机制，SUDEP是癫痫患者死亡的主要和可预防的原因。最近的证据表明，功能障碍的离子通道和受体共表达在脑，自主神经，心脏和呼吸途径，沿着临床措施的功能障碍，在这些途径的时间周围癫痫发作代表可检测和潜在的可治疗的风险因素SUDEP。该提案描述了一个综合的多中心和多学科合作项目，该项目将联合收割机结合基础科学、人类神经遗传学和临床生理学方法，在实验室到床边的转化研究计划中研究这些生物风险因素，以识别、验证和临床评估SUDEP的预测性生物标志物和预防性治疗。SUDEP中心研究管道将由中心6名研究人员之间的连续相互关联的工作流程组成。项目1（Baylor）将扩大来自3个中心（EMU、Dravet综合征诊所、SUDEP DNA库）和其他国家网络的患者DNA样本库，这些样本将使用芯片微阵列分析>247个介导心律失常、呼吸抑制和癫痫的优先离子通道和受体基因。项目2-4（贝勒大学）密歇根大学爱荷华州）在SUDEP小鼠模型和来自Dravet综合征病例的诱导多能干细胞中，在细胞和体内水平分析这些和相关基因突变的生物学、生理学和药理学，以理解和验证SUDEP表型。项目5（U.C.戴维斯/儿童纪念芝加哥）将完善临床呼吸和心脏生物标志物期间获得的癫痫监测个人与Dravet综合征和其他高风险的猝死（发作性低氧血症，心律失常）。一旦得到验证，来自这些病例的基因将被添加到贝勒大学正在开发的增量诊断芯片中，用于在临床上对具有其他临床生物标志物的个体进行常规患者风险评估。 公共卫生相关性：癫痫猝死（SUDEP）是特发性癫痫过早死亡的主要原因。预防SUDEP依赖于识别癫痫患者的生物学预测风险因素，并使用它们进行适当的治疗干预。该计划的目标是验证一个综合的遗传/临床SUDEP风险特征，以筛选和治疗癫痫患者。 免责声明：请注意，以下评论是由审查员在研究部分会议之前准备的，并且以基本上未经编辑的形式提供。 虽然审查人员有机会根据小组讨论情况更新或修订其书面评价，但不能保证在会议讨论之后更新了个人评论。 因此，这些评论可能并不完全反映小组讨论结束时个人评论员的最终意见或小组的最终多数意见。因此，讨论的简历和摘要是评审员在会议上实际认为关键的最后一句话。